Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Comparison of wait times across the breast cancer treatment pathway among screened women undergoing organized breast assessment versus usual care.

Blackmore KM, Weerasinghe A, Holloway CMB, Majpruz V, Mirea L, O'Malley FP, Paroschy Harris C, Hendry A, Hey A, Kornecki A, Lougheed G, Maier BA, Marchand P, McCready D, Rand C, Raphael S, Segal-Nadler R, Sehgal N, Muradali D, Chiarelli AM.

Can J Public Health. 2019 Apr 29. doi: 10.17269/s41997-019-00210-7. [Epub ahead of print]

PMID:
31037608
2.

The impact of organized breast assessment on survival by stage for screened women diagnosed with invasive breast cancer.

Smith CR, Chiarelli AM, Holloway CM, Mirea L, O'Malley FP, Blackmore KM, Pandya A, Majpruz V, Harris CP, Hendry A, Hey A, Kornecki A, Lougheed G, Maier BA, Marchand P, McCready D, Rand C, Raphael S, Segal-Nadler R, Sehgal N, Muradali D.

Breast. 2018 Oct;41:25-33. doi: 10.1016/j.breast.2018.06.007. Epub 2018 Jun 18.

3.

Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care.

Chiarelli AM, Muradali D, Blackmore KM, Smith CR, Mirea L, Majpruz V, O'Malley FP, Quan ML, Holloway CM.

Br J Cancer. 2017 May 9;116(10):1254-1263. doi: 10.1038/bjc.2017.87. Epub 2017 Mar 30.

4.

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

Bartlett JM, McConkey CC, Munro AF, Desmedt C, Dunn JA, Larsimont DP, O'Malley FP, Cameron DA, Earl HM, Poole CJ, Shepherd LE, Cardoso F, Jensen MB, Caldas C, Twelves CJ, Rea DW, Ejlertsen B, Di Leo A, Pritchard KI.

J Clin Oncol. 2015 May 20;33(15):1680-7. doi: 10.1200/JCO.2013.54.7869. Epub 2015 Apr 20.

PMID:
25897160
5.

Diagnostic concordance among pathologists interpreting breast biopsy specimens.

Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson AN, Nelson HD, Pepe MS, Allison KH, Schnitt SJ, O'Malley FP, Weaver DL.

JAMA. 2015 Mar 17;313(11):1122-32. doi: 10.1001/jama.2015.1405.

6.

Clinical and prognostic factors associated with diagnostic wait times by breast cancer detection method.

Plotogea A, Chiarelli AM, Mirea L, Prummel MV, Chong N, Shumak RS, O'Malley FP, Holloway CM; Breast Screening Study Group.

Springerplus. 2014 Mar 6;3:125. doi: 10.1186/2193-1801-3-125. eCollection 2014.

7.

Digitized whole slides for breast pathology interpretation: current practices and perceptions.

Onega T, Weaver D, Geller B, Oster N, Tosteson AN, Carney PA, Nelson H, Allison KH, O'Malley FP, Schnitt SJ, Elmore JG.

J Digit Imaging. 2014 Oct;27(5):642-8. doi: 10.1007/s10278-014-9683-2.

8.

Intranodal papillary epithelial proliferations: a local process with a spectrum of morphologies and frequent association with papillomas in the breast.

Boulos FI, Granja NM, Simpson JF, O'Malley FP, Saadeldine MM, Page DL, Sanders ME.

Am J Surg Pathol. 2014 Mar;38(3):383-8. doi: 10.1097/PAS.0000000000000115. Erratum in: Am J Surg Pathol. 2014 May;38(5):728. Sanders, Melina E [corrected to Sanders, Melinda E].

PMID:
24525508
9.

Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel.

Allison KH, Reisch LM, Carney PA, Weaver DL, Schnitt SJ, O'Malley FP, Geller BM, Elmore JG.

Histopathology. 2014 Aug;65(2):240-51. doi: 10.1111/his.12387. Epub 2014 Apr 2.

10.

Factors associated with wait times across the breast cancer treatment pathway in Ontario.

Plotogea A, Chiarelli AM, Mirea L, Prummel MV, Chong N, Shumak RS, O'Malley FP, Holloway CM; Breast Screening Study Group.

Springerplus. 2013 Aug 19;2:388. doi: 10.1186/2193-1801-2-388. eCollection 2013.

11.

Impact of familial risk and mammography screening on prognostic indicators of breast disease among women from the Ontario site of the Breast Cancer Family Registry.

Walker MJ, Mirea L, Cooper K, Nabavi M, Glendon G, Andrulis IL, Knight JA, O'Malley FP, Chiarelli AM.

Fam Cancer. 2014 Jun;13(2):163-72. doi: 10.1007/s10689-013-9689-9.

PMID:
24097051
12.

Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers.

Bane A, Viloria-Petit A, Pinnaduwage D, Mulligan AM, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2013 Jul;140(1):195-205. doi: 10.1007/s10549-013-2591-1. Epub 2013 Jun 28.

13.

Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer.

Forse CL, Yilmaz YE, Pinnaduwage D, O'Malley FP, Mulligan AM, Bull SB, Andrulis IL.

Breast Cancer Res Treat. 2013 Feb;137(3):709-19. doi: 10.1007/s10549-012-2392-y. Epub 2013 Jan 4.

PMID:
23288345
14.

Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.

Mulligan AM, Raitman I, Feeley L, Pinnaduwage D, Nguyen LT, O'Malley FP, Ohashi PS, Andrulis IL.

Clin Cancer Res. 2013 Jan 15;19(2):336-46. doi: 10.1158/1078-0432.CCR-11-3314. Epub 2012 Dec 4.

15.

Improving work-up of the abnormal mammogram through organized assessment: results from the ontario breast screening program.

Quan ML, Shumak RS, Majpruz V, Holloway CM, O'Malley FP, Chiarelli AM.

J Oncol Pract. 2012 Mar;8(2):107-12. doi: 10.1200/JOP.2011.000413. Epub 2012 Feb 14.

16.

Prospective study of 2-[¹⁸F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: an Ontario clinical oncology group study.

Pritchard KI, Julian JA, Holloway CM, McCready D, Gulenchyn KY, George R, Hodgson N, Lovrics P, Perera F, Elavathil L, O'Malley FP, Down N, Bodurtha A, Shelley W, Levine MN.

J Clin Oncol. 2012 Apr 20;30(12):1274-9. doi: 10.1200/JCO.2011.38.1103. Epub 2012 Mar 5.

PMID:
22393089
17.

Papillary lesions of the breast: impact of breast pathology subspecialization on core biopsy and excision diagnoses.

Jakate K, De Brot M, Goldberg F, Muradali D, O'Malley FP, Mulligan AM.

Am J Surg Pathol. 2012 Apr;36(4):544-51. doi: 10.1097/PAS.0b013e318243fa00.

PMID:
22314186
18.

Favourable prognostic factors of subsequent screen-detected breast cancers among women aged 50-69.

Chiarelli AM, Edwards SA, Sheppard AJ, Mirea L, Chong N, Paszat L, Shumak RS, Oʼmalley FP; Breast Screening Study Group.

Eur J Cancer Prev. 2012 Nov;21(6):499-506. Review.

PMID:
22273849
19.

TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.

Hertel PB, Tu D, Ejlertsen B, Jensen MB, Balslev E, Jiang S, O'Malley FP, Pritchard KI, Shepherd LE, Bartels A, Brünner N, Nielsen TO.

Breast Cancer Res Treat. 2012 Feb;132(1):225-34. doi: 10.1007/s10549-011-1896-1. Epub 2011 Dec 9.

PMID:
22160637
20.

Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.

Goodwin PJ, Phillips KA, West DW, Ennis M, Hopper JL, John EM, O'Malley FP, Milne RL, Andrulis IL, Friedlander ML, Southey MC, Apicella C, Giles GG, Longacre TA.

J Clin Oncol. 2012 Jan 1;30(1):19-26. doi: 10.1200/JCO.2010.33.0068. Epub 2011 Dec 5.

PMID:
22147742
21.

Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2.

Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, Janavicius R, Hansen Tv, Nielsen FC, Ejlertsen B, Osorio A, Muñoz-Repeto I, Durán M, Godino J, Pertesi M, Benítez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Bonanni B, Viel A, Pasini B, Papi L, Ottini L, Savarese A, Bernard L, Radice P, Hamann U, Verheus M, Meijers-Heijboer HE, Wijnen J, Gómez García EB, Nelen MR, Kets CM, Seynaeve C, Tilanus-Linthorst MM, van der Luijt RB, van Os T, Rookus M, Frost D, Jones JL, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Cook J, Donaldson A, Dorkins H, Gregory H, Eason J, Houghton C, Barwell J, Side LE, McCann E, Murray A, Peock S, Godwin AK, Schmutzler RK, Rhiem K, Engel C, Meindl A, Ruehl I, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Kast K, Preisler-Adams S, Varon-Mateeva R, Schoenbuchner I, Fiebig B, Heinritz W, Schäfer D, Gevensleben H, Caux-Moncoutier V, Fassy-Colcombet M, Cornelis F, Mazoyer S, Léoné M, Boutry-Kryza N, Hardouin A, Berthet P, Muller D, Fricker JP, Mortemousque I, Pujol P, Coupier I, Lebrun M, Kientz C, Longy M, Sevenet N, Stoppa-Lyonnet D, Isaacs C, Caldes T, de la Hoya M, Heikkinen T, Aittomäki K, Blanco I, Lazaro C, Barkardottir RB, Soucy P, Dumont M, Simard J, Montagna M, Tognazzo S, D'Andrea E, Fox S, Yan M, Rebbeck T, Olopade O, Weitzel JN, Lynch HT, Ganz PA, Tomlinson GE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet M, Bhatia J, Kauff N, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Mai PL, Greene MH, Imyanitov E, O'Malley FP, Ozcelik H, Glendon G, Toland AE, Gerdes AM, Thomassen M, Kruse TA, Jensen UB, Skytte AB, Caligo MA, Soller M, Henriksson K, Wachenfeldt vA, Arver B, Stenmark-Askmalm M, Karlsson P, Ding YC, Neuhausen SL, Beattie M, Pharoah PD, Moysich KB, Nathanson KL, Karlan BY, Gross J, John EM, Daly MB, Buys SM, Southey MC, Hopper JL, Terry MB, Chung W, Miron AF, Goldgar D, Chenevix-Trench G, Easton DF, Andrulis IL, Antoniou AC; Breast Cancer Family Registry; EMBRACE; GEMO Study Collaborators; HEBON; kConFab Investigators; Ontario Cancer Genetics Network; SWE-BRCA; CIMBA.

Breast Cancer Res. 2011;13(6):R110. doi: 10.1186/bcr3052. Epub 2011 Nov 2.

22.

Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.

Pritchard KI, Munro A, O'Malley FP, Tu D, Li X, Levine MN, Shepherd L, Chia S, Bartlett JM.

Breast Cancer Res Treat. 2012 Jan;131(2):541-51. doi: 10.1007/s10549-011-1840-4. Epub 2011 Nov 1.

PMID:
22042366
23.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M; HER2/TOP2A Meta-analysis Study Group.

Lancet Oncol. 2011 Nov;12(12):1134-42. doi: 10.1016/S1470-2045(11)70231-5. Epub 2011 Sep 12.

24.

Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium.

Figueroa JD, Garcia-Closas M, Humphreys M, Platte R, Hopper JL, Southey MC, Apicella C, Hammet F, Schmidt MK, Broeks A, Tollenaar RA, Van't Veer LJ, Fasching PA, Beckmann MW, Ekici AB, Strick R, Peto J, dos Santos Silva I, Fletcher O, Johnson N, Sawyer E, Tomlinson I, Kerin M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Bojesen S, Flyger H, Nordestgaard BG, Benítez J, Milne RL, Ignacio Arias J, Zamora MP, Brenner H, Müller H, Arndt V, Rahman N, Turnbull C, Seal S, Renwick A, Brauch H, Justenhoven C, Brüning T; GENICA Network, Chang-Claude J, Hein R, Wang-Gohrke S, Dörk T, Schürmann P, Bremer M, Hillemanns P, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Bogdanova N, Antonenkova N, Rogov YI, Karstens JH, Bermisheva M, Prokofieva D, Gantcev SH, Khusnutdinova E, Lindblom A, Margolin S, Chenevix-Trench G, Beesley J, Chen X; kConFab AOCS Management Group, Mannermaa A, Kosma VM, Soini Y, Kataja V, Lambrechts D, Yesilyurt BT, Chrisiaens MR, Peeters S, Radice P, Peterlongo P, Manoukian S, Barile M, Couch F, Lee AM, Diasio R, Wang X, Giles GG, Severi G, Baglietto L, Maclean C, Offit K, Robson M, Joseph V, Gaudet M, John EM, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis I, Knight JA, Mulligan AM, O'Malley FP, Brinton LA, Sherman ME, Lissowska J, Chanock SJ, Hooning M, Martens JW, van den Ouweland AM, Collée JM, Hall P, Czene K, Cox A, Brock IW, Reed MW, Cross SS, Pharoah P, Dunning AM, Kang D, Yoo KY, Noh DY, Ahn SH, Jakubowska A, Lubinski J, Jaworska K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Shen CY, Ding SL, Hsu HM, Yu JC, Anton-Culver H, Ziogas A, Ashworth A, Swerdlow A, Jones M, Orr N, Trentham-Dietz A, Egan K, Newcomb P, Titus-Ernstoff L, Easton D, Spurdle AB.

Hum Mol Genet. 2011 Dec 1;20(23):4693-706. doi: 10.1093/hmg/ddr368. Epub 2011 Aug 18.

25.

Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium.

Broeks A, Schmidt MK, Sherman ME, Couch FJ, Hopper JL, Dite GS, Apicella C, Smith LD, Hammet F, Southey MC, Van 't Veer LJ, de Groot R, Smit VT, Fasching PA, Beckmann MW, Jud S, Ekici AB, Hartmann A, Hein A, Schulz-Wendtland R, Burwinkel B, Marme F, Schneeweiss A, Sinn HP, Sohn C, Tchatchou S, Bojesen SE, Nordestgaard BG, Flyger H, Ørsted DD, Kaur-Knudsen D, Milne RL, Pérez JI, Zamora P, Rodríguez PM, Benítez J, Brauch H, Justenhoven C, Ko YD; Genica Network, Hamann U, Fischer HP, Brüning T, Pesch B, Chang-Claude J, Wang-Gohrke S, Bremer M, Karstens JH, Hillemanns P, Dörk T, Nevanlinna HA, Heikkinen T, Heikkilä P, Blomqvist C, Aittomäki K, Aaltonen K, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Kauppinen JM, Kataja V, Auvinen P, Eskelinen M, Soini Y, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Holland H; kConFab; AOCS, Lambrechts D, Claes B, Vandorpe T, Neven P, Wildiers H, Flesch-Janys D, Hein R, Löning T, Kosel M, Fredericksen ZS, Wang X, Giles GG, Baglietto L, Severi G, McLean C, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Alnæs GG, Kristensen V, Børresen-Dale AL, Hunter DJ, Hankinson SE, Andrulis IL, Mulligan AM, O'Malley FP, Devilee P, Huijts PE, Tollenaar RA, Van Asperen CJ, Seynaeve CS, Chanock SJ, Lissowska J, Brinton L, Peplonska B, Figueroa J, Yang XR, Hooning MJ, Hollestelle A, Oldenburg RA, Jager A, Kriege M, Ozturk B, van Leenders GJ, Hall P, Czene K, Humphreys K, Liu J, Cox A, Connley D, Cramp HE, Cross SS, Balasubramanian SP, Reed MW, Dunning AM, Easton DF, Humphreys MK, Caldas C, Blows F, Driver K, Provenzano E, Lubinski J, Jakubowska A, Huzarski T, Byrski T, Cybulski C, Gorski B, Gronwald J, Brennan P, Sangrajrang S, Gaborieau V, Shen CY, Hsiung CN, Yu JC, Chen ST, Hsu GC, Hou MF, Huang CS, Anton-Culver H, Ziogas A, Pharoah PD, Garcia-Closas M.

Hum Mol Genet. 2011 Aug 15;20(16):3289-303. doi: 10.1093/hmg/ddr228. Epub 2011 May 19.

26.

Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program.

Kirsh VA, Chiarelli AM, Edwards SA, O'Malley FP, Shumak RS, Yaffe MJ, Boyd NF.

J Natl Cancer Inst. 2011 Jun 22;103(12):942-50. doi: 10.1093/jnci/djr138. Epub 2011 May 3.

PMID:
21540443
27.

Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.

O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman D, Bramwell VH, Andrulis IL, Pritchard KI.

Breast Cancer Res Treat. 2011 Jul;128(2):401-9. doi: 10.1007/s10549-011-1511-5. Epub 2011 Apr 26.

PMID:
21519837
28.

CK8/18 expression, the basal phenotype, and family history in identifying BRCA1-associated breast cancer in the Ontario site of the breast cancer family registry.

Mulligan AM, Pinnaduwage D, Bane AL, Bull SB, O'Malley FP, Andrulis IL.

Cancer. 2011 Apr 1;117(7):1350-9. doi: 10.1002/cncr.25642. Epub 2010 Nov 2.

29.

EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry.

Bane AL, Mulligan AM, Pinnaduwage D, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2011 Jun;127(3):831-9. doi: 10.1007/s10549-011-1380-y. Epub 2011 Feb 15.

PMID:
21327470
30.

Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry.

Smith LD, Tesoriero AA, Wong EM, Ramus SJ, O'Malley FP, Mulligan AM, Terry MB, Senie RT, Santella RM, John EM, Andrulis IL, Ozcelik H, Daly MB, Godwin AK, Buys SS, Fox S, Goldgar DE, Giles GG, Hopper JL, Southey MC.

Breast Cancer Res. 2011 Jan 31;13(1):R14. doi: 10.1186/bcr2822.

31.

Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.

Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, Milne RL, Gaudet M, Schmidt MK, Broeks A, Cox A, Fasching PA, Hein R, Spurdle AB, Blows F, Driver K, Flesch-Janys D, Heinz J, Sinn P, Vrieling A, Heikkinen T, Aittomäki K, Heikkilä P, Blomqvist C, Lissowska J, Peplonska B, Chanock S, Figueroa J, Brinton L, Hall P, Czene K, Humphreys K, Darabi H, Liu J, Van 't Veer LJ, van Leeuwen FE, Andrulis IL, Glendon G, Knight JA, Mulligan AM, O'Malley FP, Weerasooriya N, John EM, Beckmann MW, Hartmann A, Weihbrecht SB, Wachter DL, Jud SM, Loehberg CR, Baglietto L, English DR, Giles GG, McLean CA, Severi G, Lambrechts D, Vandorpe T, Weltens C, Paridaens R, Smeets A, Neven P, Wildiers H, Wang X, Olson JE, Cafourek V, Fredericksen Z, Kosel M, Vachon C, Cramp HE, Connley D, Cross SS, Balasubramanian SP, Reed MW, Dörk T, Bremer M, Meyer A, Karstens JH, Ay A, Park-Simon TW, Hillemanns P, Arias Pérez JI, Menéndez Rodríguez P, Zamora P, Benítez J, Ko YD, Fischer HP, Hamann U, Pesch B, Brüning T, Justenhoven C, Brauch H, Eccles DM, Tapper WJ, Gerty SM, Sawyer EJ, Tomlinson IP, Jones A, Kerin M, Miller N, McInerney N, Anton-Culver H, Ziogas A, Shen CY, Hsiung CN, Wu PE, Yang SL, Yu JC, Chen ST, Hsu GC, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Lindblom A, Margolin S, Jakubowska A, Lubiński J, Huzarski T, Byrski T, Górski B, Gronwald J, Hooning MJ, Hollestelle A, van den Ouweland AM, Jager A, Kriege M, Tilanus-Linthorst MM, Collée M, Wang-Gohrke S, Pylkäs K, Jukkola-Vuorinen A, Mononen K, Grip M, Hirvikoski P, Winqvist R, Mannermaa A, Kosma VM, Kauppinen J, Kataja V, Auvinen P, Soini Y, Sironen R, Bojesen SE, Ørsted DD, Kaur-Knudsen D, Flyger H, Nordestgaard BG, Holland H, Chenevix-Trench G, Manoukian S, Barile M, Radice P, Hankinson SE, Hunter DJ, Tamimi R, Sangrajrang S, Brennan P, McKay J, Odefrey F, Gaborieau V, Devilee P, Huijts PE, Tollenaar RA, Seynaeve C, Dite GS, Apicella C, Hopper JL, Hammet F, Tsimiklis H, Smith LD, Southey MC, Humphreys MK, Easton D, Pharoah P, Sherman ME, Garcia-Closas M.

J Natl Cancer Inst. 2011 Feb 2;103(3):250-63. doi: 10.1093/jnci/djq526. Epub 2010 Dec 29.

32.

Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers.

Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olopade OI, Domchek SM, Ford J, Isaacs C, Brown P, Balmana J, Razzak AR, Miron P, Coffey K, Terry MB, John EM, Andrulis IL, Knight JA, O'Malley FP, Daly M, Bender P; kConFab, Moore R, Southey MC, Hopper JL, Garber JE, Huntsman DG.

J Med Genet. 2011 Jan;48(1):64-8. doi: 10.1136/jmg.2010.079814. Epub 2010 Oct 4.

33.

Lobular neoplasia: morphology, biological potential and management in core biopsies.

O'Malley FP.

Mod Pathol. 2010 May;23 Suppl 2:S14-25. doi: 10.1038/modpathol.2010.35. Review.

34.

Activity of fulvestrant in HER2-overexpressing advanced breast cancer.

Robertson JF, Steger GG, Neven P, Barni S, Gieseking F, Nolè F, Pritchard KI, O'Malley FP, Simon SD, Kaufman B, Petruzelka L.

Ann Oncol. 2010 Jun;21(6):1246-53. doi: 10.1093/annonc/mdp447. Epub 2009 Oct 29.

PMID:
19875750
35.

Protocol for the examination of specimens from patients with invasive carcinoma of the breast.

Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Tan LK, Weaver DL, Winer E; Members of the Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2009 Oct;133(10):1515-38. doi: 10.1043/1543-2165-133.10.1515. No abstract available.

PMID:
19792042
36.

Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy.

Grin A, O'Malley FP, Mulligan AM.

Am J Surg Pathol. 2009 Nov;33(11):1615-23. doi: 10.1097/PAS.0b013e3181aec446.

PMID:
19675450
37.

A role for the TGFbeta-Par6 polarity pathway in breast cancer progression.

Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, Wong JW, Kerbel RS, O'Malley FP, Andrulis IL, Wrana JL.

Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14028-33. doi: 10.1073/pnas.0906796106. Epub 2009 Aug 10.

38.

Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.

Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12903-8. doi: 10.1073/pnas.0810402106. Epub 2009 Jul 17.

39.

Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry.

Phillips KA, Milne RL, West DW, Goodwin PJ, Giles GG, Chang ET, Figueiredo JC, Friedlander ML, Keegan TH, Glendon G, Apicella C, O'Malley FP, Southey MC, Andrulis IL, John EM, Hopper JL.

Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1792-7. doi: 10.1158/1055-9965.EPI-08-1014. Erratum in: Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2345.

40.

Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.

Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ.

Anticancer Res. 2009 May;29(5):1557-62.

41.

Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.

O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI.

J Natl Cancer Inst. 2009 May 6;101(9):644-50. doi: 10.1093/jnci/djp067. Epub 2009 Apr 28.

42.

Measuring extent of ductal carcinoma in situ in breast excision specimens: a comparison of 4 methods.

Grin A, Horne G, Ennis M, O'Malley FP.

Arch Pathol Lab Med. 2009 Jan;133(1):31-7. doi: 10.1043/1543-2165-133.1.31.

PMID:
19123733
43.

Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast.

Lester SC, Bose S, Chen YY, Connolly JL, de Baca ME, Fitzgibbons PL, Hayes DF, Kleer C, O'Malley FP, Page DL, Smith BL, Weaver DL, Winer E; Members of the Cancer Committee, College of American Pathologists.

Arch Pathol Lab Med. 2009 Jan;133(1):15-25. doi: 10.1043/1543-2165-133.1.15. No abstract available.

PMID:
19123730
44.

Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry.

Chang ET, Milne RL, Phillips KA, Figueiredo JC, Sangaramoorthy M, Keegan TH, Andrulis IL, Hopper JL, Goodwin PJ, O'Malley FP, Weerasooriya N, Apicella C, Southey MC, Friedlander ML, Giles GG, Whittemore AS, West DW, John EM.

Breast Cancer Res Treat. 2009 Sep;117(1):167-76. doi: 10.1007/s10549-008-0255-3. Epub 2008 Nov 26.

45.

Prognostic effect of basal-like breast cancers is time dependent: evidence from tissue microarray studies on a lymph node-negative cohort.

Mulligan AM, Pinnaduwage D, Bull SB, O'Malley FP, Andrulis IL.

Clin Cancer Res. 2008 Jul 1;14(13):4168-74. doi: 10.1158/1078-0432.CCR-07-4543.

46.

Expression profiling of familial breast cancers demonstrates higher expression of FGFR2 in BRCA2-associated tumors.

Bane AL, Pinnaduwage D, Colby S, Reedijk M, Egan SE, Bull SB, O'Malley FP, Andrulis IL.

Breast Cancer Res Treat. 2009 Sep;117(1):183-91. doi: 10.1007/s10549-008-0087-1. Epub 2008 Jun 18. Erratum in: Breast Cancer Res Treat. 2011 Feb;126(1):269. Reedijk, Michael [added]; Egan, Sean E [added].

47.

HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.

O'Malley FP, Thomson T, Julian J, Have C, Cosby R, Gelmon K, Andrulis I, Whelan T.

Arch Pathol Lab Med. 2008 Jan;132(1):61-5. doi: 10.1043/1543-2165(2008)132[61:HTIAPS]2.0.CO;2. Erratum in: Arch Pathol Lab Med.2008 May;132(5):730. Crosby, Roxanne [corrected to Cosby, Roxanne].

PMID:
18181675
48.

An update on apocrine lesions of the breast.

O'Malley FP, Bane A.

Histopathology. 2008 Jan;52(1):3-10. doi: 10.1111/j.1365-2559.2007.02888.x. Review.

PMID:
18171412
49.

JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer.

Reedijk M, Pinnaduwage D, Dickson BC, Mulligan AM, Zhang H, Bull SB, O'Malley FP, Egan SE, Andrulis IL.

Breast Cancer Res Treat. 2008 Oct;111(3):439-48. Epub 2007 Nov 8.

PMID:
17990101
50.

Granular cell tumour of the breast: MRI findings and review of the literature.

Scaranelo AM, Bukhanov K, Crystal P, Mulligan AM, O'Malley FP.

Br J Radiol. 2007 Dec;80(960):970-4. Epub 2007 Oct 16.

PMID:
17940129

Supplemental Content

Loading ...
Support Center